Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
ASCPT 2024 | Colorado Springs, CO
Mar 27 - 29, 2024
Poster
The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader in Healthy Adult ParticipantsASCPT 2024 | Colorado Springs, CO
Mar 27 - 29, 2024
Poster
The Effect of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, on Dabigatran Pharmacokinetics in Healthy Adult ParticipantsASCPT 2024 | Colorado Springs, CO
Mar 27 - 29, 2024
Poster
Evaluation of the Effect of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, on Rosuvastatin Pharmacokinetics in Healthy Adult ParticipantsASCPT 2024 | Colorado Springs, CO
Mar 27 - 29, 2024
Poster
Drug-Drug Interaction Study of the PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Combination With the P-glycoprotein Substrate Fexofenadine in Healthy Male VolunteersASCO-GU 2024 | San Francisco, CA
Jan 25 - 27, 2024
Poster
Real-World Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Tumors Harboring Androgen Receptor (AR) Ligand-Binding Domain (LBD) MutationsSABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023
Presentation
Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Palbociclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase 1b CohortSABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023
Poster
Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER–Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast CancerSABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023
Poster
TACTIVE-U: Phase 1b/2 Umbrella Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Combined With Other Anticancer Treatments in ER-Positive Advanced or Metastatic Breast CancerSABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023